BRN: 714354

"Four months into the coronavirus pandemic, as the death count surged, the FDA made a risky decision: it approved an anti-malarial drug as a treatment for coronavirus, despite limited data on its efficacy or side effects. A month later, the FDA withdrew its recommendation, but by then, the damage...